At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab
In Brief
An observational study evaluating Rituximab for Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Completed, enrolled 100 participants across 15 sites.
Detailed Summary
This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on MabThera/Rituxan therapy by their physician according to prescribing information.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartJun 2012
Primary CompletionJul 2015
Study CompletionApr 2017
TodayJul 2026
First PostedJun 7, 2012
Enrollment StartJun 20, 2012
Primary CompletionJul 13, 2015
Study CompletionApr 28, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.1 years ago
Interventions
Rituximabdrug
Participants received rituximab at the discretion of their treating physicians.